New Rheumatoid Arthritis Risk Stratification Criteria Released

Ruth Jessen Hickman, MD, a graduate of the Indiana University School of Medicine, is a medical and science writer in Bloomington, Ind.

References

1. van Steenbergen HW, Doornkamp F, Alivernini S, et al. EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia. Arthritis Rheumatol. 2025 May 8. Online ahead of print.
2. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep;62(9):2569–2581.
3. Gerlag DM, Safy M, Maijer KI, et al. Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: The PRAIRI study. Ann Rheum Dis. 2019 Feb;78(2):179–185.
4. Deane KD, Striebich CC, Feser ML, et al. A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis. Arthritis Rheumatol. 2025 Aug 29. Online ahead of print.
5. Cope AP, Jasenecova M, Vasconcelos JC, et al. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): A randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet. 2024 Mar 2;403(10429):838–849.
6. Rech J, Tascilar K, Hagen M, et al. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet. 2024 Mar 2;403(10429):850–859
7. Krijbolder DI, Verstappen M, van Dijk BT, et al. Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): A randomised, double-blind, placebo-con-trolled, proof-of-concept trial. Lancet. 2022 Jul 23;400(10348):283–294.
8. Mankia K, Siddle H, Di Matteo A, et al. A core set of risk factors in individuals at risk of rheumatoid arthritis: A systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. RMD Open. 2021 Sep;7(3):e001768.
9. Mankia K, Siddle HJ, Kerschbaumer A, et al. EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Ann Rheum Dis. 2021 Oct;80(10):1286–1298.
10. Duquenne L, Hensor EM, Wilson M, et al. Predicting inflammatory arthritis in at-risk persons: Development of scores for risk stratification. Ann Intern Med. 2023 Aug;176(8):1027–1036.
11. Di Matteo A, De Lorenzis E, Duquenne L, et al. Ultrasound in anti-CCP+ at-risk individuals without clinical synovitis: development of a novel 6-joint protocol for feasible risk prediction. Rheumatology (Oxford). 2024 Aug 1;63(8):2213–2221.
12. Di Matteo A, Mankia K, Duquenne L, et al. Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis. Ann Rheum Dis. 2020 Jul;79(7):901–907.
13. Ziegelasch M, Eloff E, Hammer HB, et al. Bone erosions detected by ultrasound are prognostic for clinical arthritis development in patients with ACPA and musculoskeletal pain. Front Med (Lausanne). 2021 Mar 23;8:653994.
14. Herold KC, Bundy BN, Long SA. An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N Engl J Med. 2019 Aug 15;381(7):603–613. Erratum in N Engl J Med. 2020 Feb 6;382(6):586.